Facebook Linkedin Pinterest Reddit Twitter
NON PROFIT
1 min.Read

ACC CardioOncology Course Aims to Help Clinicians Improve Survival, Quality of Life of Oncology Patients

Course to showcase latest research, evidence-based treatment strategies and best practices in growing field of cardiooncology

ACC – The American College of Cardiology will host the annual Advancing the Cardiovascular Care of the Oncology Patient virtual course with live sessions on Feb. 11-12, 2022, as well as on demand content. The course is intended for members of the entire interprofessional team, including cardiologists, oncologists, internists, pharmacists and nurses who provide health care to the growing population of cancer patients and survivors with cardiovascular concerns.

Experts from across the entire multidisciplinary care team will educate on improving awareness, identification, monitoring and management of cardiovascular diseases and conditions, as well as how to minimize cardiotoxicity from cancer therapies to help clinicians improve overall survival and quality of life for oncology patients.

Course co-directors Ana Barac, MD, PhD, FACC, and Bonnie Ky, MD, MSCE, FACC, have worked with respected experts in the field to create a course that will help the entire interprofessional team, at all levels of their careers, understand the different types of cancer therapies and how to mitigate the associated cardiovascular complications. The course will feature the latest research, best practices and case discussions on evidence-based treatment strategies with practical tips to comprehensively care for cancer patients and survivors.

Sessions Include:

  • Building Bridges in Cardio-Oncology – How to Improve Outcomes in Cancer Patients and Survivors
  • Immune Therapy and Cardiovascular Risk: What Do We Know and Where Does the Field Need to Go?
  • Cardioprotection: What Have the Clinical Trials Told Us?
  • The Growing Intersection Between CV Disease and Cancer: From Biology to Epidemiology
  • Health Care Disparities – How Can We Achieve Health Equity?

Posters

The following abstracts are a selection of posters being presented. All ACC Advancing the Cardiovascular Care of the Oncology Patients posters and abstracts are embargoed until Friday, Feb. 11 at 7 a.m. ET.

  • Assessment of Cardiovascular Disease Risk Factor Control in Triple Negative Breast Cancer Patients
  • Cardiovascular Disease in Patients with Thymic Cancer
  • Coronary Artery Calcium Burden as a Risk Factor for Adverse Cardiovascular Events in Patients with Lung Cancer Receiving Radiation Therapy (press release to follow)
  • Effectiveness of Virtual Cardio-Oncology Zoom Clinics on Long-term Patient Safety and Positive Satisfaction in a Tertiary Care Centre During COVID Pandemics
SourceAmerican College of Cardiology

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330

Exit mobile version